Showing results (191-200 of 250) with videos related to
Sort By:
Pageof 25
American Journal of Cancer Research|January 27, 2017
The fate of BRCA1-related germline mutations in triple-negative breast tumorsVassiliki Kotoula, Florentia Fostira, Kyriaki Papadopoulou, et al.Plos One|June 9, 2012
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.BMC Cancer|July 17, 2014
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialGeorge Fountzilas, Urania Dafni, Christos Papadimitriou, et al.British Journal of Cancer|May 24, 2022
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 TrialFlora Zagouri, Georgia-Angeliki Koliou, Foteinos Dimitrakopoulos, et al.The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.Plos One|August 8, 2013
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)George Pentheroudakis, Vassiliki Kotoula, Anastasia G Eleftheraki, et al.Oncotarget|April 30, 2016
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingGeorge Fountzilas, Eleni Giannoulatou, Zoi Alexopoulou, et al.Nature Communications|June 1, 2017
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesionsAntje Sucker, Fang Zhao, Natalia Pieper, et al.Pageof 25